Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children

A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose

This study will evaluate the safety and immunogenicity of single dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 13-59 months of age.

Inclusion Criteria:

• Infants 13-59 months of age.

Exclusion Criteria:

• Prior Hib vaccine administration.
• History of serious reaction(s) following vaccination.
• Any vaccination within 7 days of study vaccination.
• Known or suspected immune impairment.
• Premature (before 37th week of gestation) or birth weight less than 2500g
• For additional entry criteria please refer to the protocol.